JP2018535701A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535701A5
JP2018535701A5 JP2018546725A JP2018546725A JP2018535701A5 JP 2018535701 A5 JP2018535701 A5 JP 2018535701A5 JP 2018546725 A JP2018546725 A JP 2018546725A JP 2018546725 A JP2018546725 A JP 2018546725A JP 2018535701 A5 JP2018535701 A5 JP 2018535701A5
Authority
JP
Japan
Prior art keywords
cell
item
antigen
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535701A (ja
JP6976960B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/051141 external-priority patent/WO2017088012A1/en
Publication of JP2018535701A publication Critical patent/JP2018535701A/ja
Publication of JP2018535701A5 publication Critical patent/JP2018535701A5/ja
Priority to JP2021183110A priority Critical patent/JP2022027762A/ja
Application granted granted Critical
Publication of JP6976960B2 publication Critical patent/JP6976960B2/ja
Priority to JP2024010098A priority patent/JP2024028648A/ja
Priority to JP2025265629A priority patent/JP2026034683A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546725A 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用 Active JP6976960B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021183110A JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用
JP2024010098A JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A JP2026034683A (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015904933 2015-11-27
AU2015904933A AU2015904933A0 (en) 2015-11-27 Genetically modified cells and uses thereof
AU2016901328A AU2016901328A0 (en) 2016-04-11 Genetically modified cells and uses thereof - III
AU2016901328 2016-04-11
PCT/AU2016/051141 WO2017088012A1 (en) 2015-11-27 2016-11-23 Genetically modified cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021183110A Division JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2018535701A JP2018535701A (ja) 2018-12-06
JP2018535701A5 true JP2018535701A5 (https=) 2019-12-26
JP6976960B2 JP6976960B2 (ja) 2021-12-08

Family

ID=58762790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018546725A Active JP6976960B2 (ja) 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用
JP2021183110A Pending JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用
JP2024010098A Pending JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A Pending JP2026034683A (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021183110A Pending JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用
JP2024010098A Pending JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A Pending JP2026034683A (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Country Status (11)

Country Link
US (3) US11400145B2 (https=)
EP (3) EP3708587B1 (https=)
JP (4) JP6976960B2 (https=)
CN (2) CN109152824B (https=)
AU (2) AU2016361451B2 (https=)
CA (1) CA3004120A1 (https=)
ES (2) ES2988976T3 (https=)
IL (2) IL296410A (https=)
MY (1) MY189819A (https=)
SG (2) SG11201803493UA (https=)
WO (1) WO2017088012A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978186A1 (en) 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
EP3708587B1 (en) * 2015-11-27 2024-05-22 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
JP7114490B2 (ja) * 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
NZ750256A (en) 2016-08-03 2026-02-27 Dipersio John F Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
EP3510145A4 (en) 2016-09-06 2020-03-25 The Children's Medical Center Corporation IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
AU2018236461B2 (en) 2017-03-17 2025-03-27 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
US12303561B2 (en) 2017-04-03 2025-05-20 Biontech Us Inc. Protein antigens and uses thereof
WO2018195175A1 (en) * 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
EP3697438A4 (en) * 2017-10-18 2021-08-18 Intrexon Corporation POLYPEPTIDE COMPOSITIONS WITH SPACERS
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
CA3090791A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
US12281150B2 (en) 2018-02-23 2025-04-22 Cartherics Pty. Ltd. T cell disease treatment targeting TAG-72
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
GB201807945D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
JP2022516389A (ja) * 2018-05-31 2022-02-28 ワシントン・ユニバーシティ 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
CA3108381A1 (en) * 2018-08-01 2020-02-06 City Of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
AU2020291457B2 (en) * 2019-06-12 2024-11-14 The Regents Of The University Of California Engineered off-the-shelf immune cells and methods of use thereof
AU2020393334A1 (en) 2019-11-25 2022-06-16 Kyoto University T-cell master cell bank
BR112022023371A2 (pt) * 2020-05-22 2022-12-20 Chongqing Prec Biotech Co Ltd Proteína de fusão para reversão do microambiente tumoral, vetor de expressão, célula imune, receptor de antígeno quimérico resistente à imunossupressão tumoral, sequência de ácido nucleico, método para preparar uma célula imune, composição farmacêutica, e, uso da composição farmacêutica
CN115867294A (zh) 2020-06-04 2023-03-28 凯瑞斯马治疗公司 嵌合抗原受体的新型构建体
WO2022061837A1 (en) * 2020-09-27 2022-03-31 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Fibronectin extra domain b (edb) -specific car-t for cancer
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US20220333074A1 (en) * 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
MX2023011927A (es) * 2021-04-07 2023-10-23 Century Therapeutics Inc Composiciones y metodos para la generacion de linfocitos t gamma-delta a partir de celulas madre pluripotentes inducidas.
WO2023110824A1 (en) * 2021-12-15 2023-06-22 Novo Nordisk A/S Novel integrin associated protein (iap)
CN114573710A (zh) * 2022-02-16 2022-06-03 南方医科大学珠江医院 一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用
WO2024036214A2 (en) * 2022-08-10 2024-02-15 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
EP0937095A4 (en) * 1996-10-25 1999-12-22 Cell Genesys Inc TARGETED CYTOLYSIS OF CANCER CELLS
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
CA2375974C (en) 1999-06-29 2010-11-02 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
DE10130800B4 (de) 2001-06-22 2005-06-23 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003273542A1 (en) 2002-05-31 2003-12-19 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying and isolating stem cells and cancer stem cells
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
ES2378524T3 (es) 2002-09-13 2012-04-13 The Board Of Trustees Of The Leland Stanford Junior University Célula progenitora de megacariocitos de mamífero
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
US20080241884A1 (en) * 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
JP4970948B2 (ja) 2003-12-05 2012-07-11 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 癌幹細胞の同定、単離、および除去の方法
WO2005123909A2 (en) 2004-06-09 2005-12-29 The Board Of Trustees Of The Leland Stanford Junior University Isolation and characterization of muscle regenerating cells
US7641897B2 (en) 2004-11-23 2010-01-05 The Board Of Trustees Of The Leland Stanford Junior University Feeder layer and serum independent embryonic stem cells
US20060188508A1 (en) 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
DK1877102T3 (da) * 2005-04-28 2014-07-21 Danisco Us Inc Tab-molekyler
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2695896B1 (en) 2006-10-06 2018-08-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
US7781179B2 (en) 2006-12-07 2010-08-24 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of transitional cell carcinoma stem cells
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
US8765390B2 (en) 2006-12-08 2014-07-01 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of squamous carcinoma stem cells
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
US8320687B2 (en) 2009-02-05 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Universal lossy compression methods
DK2438160T3 (en) * 2009-06-05 2016-01-11 Cellular Dynamics Int Inc Reprogramming of T cells and hematopoietic cells
JP2012531212A (ja) * 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
EP2477648B1 (en) 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
WO2011094538A1 (en) 2010-01-29 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Depletion of teratoma-forming pluripotent stem cells
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
KR20140033029A (ko) * 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013126712A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
LT4461308T (lt) 2012-07-13 2025-06-10 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo valdymas
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
US9045734B2 (en) 2012-07-31 2015-06-02 The Board Of Trustees Of The Leland Stanford Junior University Isolation and characterization of progenitor cells from mesothelium
WO2014075788A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
AU2014248119B2 (en) 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
MX389160B (es) * 2013-10-31 2025-03-20 Hutchinson Fred Cancer Res Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas.
ES2792849T3 (es) * 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
WO2016154628A1 (en) * 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
JP6928604B2 (ja) * 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CN105331586B (zh) * 2015-11-20 2020-09-15 上海细胞治疗研究院 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途
EP3708587B1 (en) * 2015-11-27 2024-05-22 Cartherics Pty. Ltd. Genetically modified cells and uses thereof

Similar Documents

Publication Publication Date Title
JP2018535701A5 (https=)
JP2020533958A5 (https=)
JP2017524367A5 (https=)
JP2022002546A (ja) 細胞
JP2021500881A5 (https=)
JP2020517295A5 (https=)
CA3158025C (en) Anti-bcma chimeric antigen receptors
JP2021137024A5 (https=)
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
JP2016520074A5 (https=)
JP2023552998A (ja) 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
JP2018532407A5 (https=)
WO2012079000A4 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
JP2018527014A5 (https=)
US11773384B2 (en) Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
EP4273175A1 (en) Novel chimeric antigen receptor and use thereof
JPWO2020061498A5 (https=)
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
CA3194577A1 (en) Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent
JPWO2020228824A5 (https=)
IL304857A (en) Preparations and methods for treating HER2 POSITIVE cancer
JPWO2022151851A5 (https=)
RU2019107136A (ru) Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор
CN115785279A (zh) 包含新型共刺激结构域的嵌合抗原受体及其用途